Abstract 407P
Background
The benefit of focal treatments, including surgery and radiotherapy, in mSTS patients has not been clear, especially for mSTS patients who had received systemic treatments.
Methods
Medical records of mSTS patients treated at National Taiwan University Hospital from 2011 to 2017 were collected. The focal tx collected included surgery (either for the primary or metastatic tumors) and radiation therapy (RT). The analysis was limited to patients who had received at least one-line of systemic treatment. Overall survival (OS) was measured from the time of mSTS diagnosis to the date of death or the last follow-up, whichever is later.
Results
A total of 199 patients, 78 (39%) de novo and 121 (61%) recurrent, mSTS were identified. The median age was 55 (range 20-89) and male to female ratio was 0.86. The most common histologies are leiomyosarcoma (16.5%), liposarcoma (15.6%), and sarcoma NOS (15.6%). Of them, 72 (36.2%) and 48 (24.1%) patients received surgery and RT, respectively. Metastatic STS patients who had received surgical treatment had a significantly better OS as compared with those who did not (median OS 21.9 vs 16.5 months, p = 0.0296). There was a trend that the OS benefit of surgery was mostly in patients with recurrence but not de novo mSTS (p for interaction = 0.08). The type of surgery (primary vs metastatic vs primary + metastatic) did not significantly affect OS (p = 0.608). Patients who received RT had a numerically better survival (median OS 24.4 vs 16.9 months, p = 0.12). In the multivariate Cox model, the OS benefit of surgery remained significant (Table).Table:
407P Adjusted hazard ratio of OS for mSTS patients who received palliative systemic treatment
HR | 95% CI | p-value | |
---|---|---|---|
Female vs male | 1.22 | (0.85, 1.76) | 0.2852 |
Age | 1.01 | (1.00, 1.02) | 0.0830 |
Histology | |||
Other | 1 | 0.0436 | |
Leiomyosarcoma + Liposarcoma | 0.65 | (0.43, 0.99) | |
Anthracycline | 1.63 | (1.12, 2.37) | 0.0109 |
Focal treatment | 0.0731 | ||
No focal treatment | 1 | ||
RT | 0.62 | (0.36, 1.08) | 0.0923 |
Surgery | 0.63 | (0.40, 0.99) | 0.0452 |
RT + Surgery | 0.55 | (0.30, 1.00) | 0.0502 |
Conclusions
Patients with mSTS had improved OS with focal treatments, especially with surgery. A multi-disciplinary team approach to include the surgeons and radiation oncologists to discuss the optimal treatment of mSTS patients should be advocated.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Eli Lilly and Company.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
357P - Application of multi-modal approach to palliation in end of life head and neck cancer pain
Presenter: Srujana Joga
Session: Poster display session
Resources:
Abstract
358P - Evaluation of continuous low dose versus standard dose capecitabine monotherapy as second/third-line chemotherapy for metastatic malignancies
Presenter: Swaroop Revannasiddaiah
Session: Poster display session
Resources:
Abstract
359P - Factors associated with economic burden among cancer patients with minor children: A cross-sectional web-based survey of an online cancer community
Presenter: Midori Yuki
Session: Poster display session
Resources:
Abstract
360P - Factors influencing treatment decisions among breast cancer patients in the Philippine general hospital cancer institute: Medical oncology outpatient clinic
Presenter: Bobby De Guzman
Session: Poster display session
Resources:
Abstract
361P - The role of volunteers in quality palliative care delivery
Presenter: NABANITA MANDAL
Session: Poster display session
Resources:
Abstract
362P - Survey to assess the efficacy of continuity of care delivered through an out of hours telephonic consultation liaison
Presenter: Rahul D. Arora
Session: Poster display session
Resources:
Abstract
366P - Activity of larotrectinib in TRK fusion cancer patients with primary central nervous system tumours
Presenter: David Ziegler
Session: Poster display session
Resources:
Abstract
367P - Molecular characteristics and efficacy of crizotinib among different subsets of MET Amplification detected by next-generation sequencing in lung cancer
Presenter: Jing Li
Session: Poster display session
Resources:
Abstract
368P - Genomic analysis of malaysian breast cancers unravel molecular differences from Caucasian breast cancers
Presenter: Soo-Hwang Teo
Session: Poster display session
Resources:
Abstract
369P - Institutional-based prospective molecular profiling of advanced solid tumours in Hong Kong: A report of 253 cases
Presenter: Herbert Loong
Session: Poster display session
Resources:
Abstract